Dr. Hoyoung Huh is the Founder of pH Pharma and also serves as Co-Chief Executive Officer & Chairman. He also is an Angel Investor. Dr. Hoyoung Huh serves as Managing Partner at Quintessa Investment. He is a Co-Founder and serves as Chairman of the Scientific Advisory Board and Business Development and Director of AntriaBio. He served as Managing Director at Konus Advisory Group. He is the Chairman of the Board of Geron and Cytomx Therapeutics. He serves as a Board Member at Eidos Therapeutics. Additionally, he serves on the board of directors of several privately-held companies. He served as CEO of BiPar Sciences, which was acquired by Sanofi; Director of Facet Biotech acquired by Abbott; Director of Calibra Medical acquired by J&J; Chairman of Epizyme; Director of Addex Pharmaceuticals; Director of EOS acquired by Clovis Oncology; Director and COO of Nektar Therapeutics; and Director of Actogenix acquired by Intrexon. Dr. Huh formerly was a partner at McKinsey & Company and physician scientist at Cornell University Medical College and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry from Dartmouth College and an M.D. and Ph.D. in genetics and cell biology from Cornell University Medical College and Sloan-Kettering Institute. He served as Board Member at Ascendancy Healthcare. He also serves as a Board Member at Shared-X.